Diffuse Drug-Induced Dermatitis following Sclerotherapy for Telangiectasias

Libby MW, Caitlin WH, Deniz OA and Heller JA*

Department of Surgery, Johns Hopkins Vein Center, Johns Hopkins Medical Centers, Baltimore, USA

*Corresponding author: Jennifer A Heller, 10755 Falls Road, Pavilion 1 Suite 360, Lutherville, MD 21903, Tel: 4105500415; Email: jheller6@jhmi.edu

Received date: June 14, 2016; Accepted date: July 26, 2016; Published date: August 02, 2016

Abstract

Sclerotherapy is an effective treatment modality for the management of lower extremity telangiectasias. Although localized dermatologic reactions are known complications of this procedure, systemic reactions are rare. Here, we present a case of a diffuse drug eruption following sclerotherapy for the treatment of bilateral lower extremity telangiectasias. Salient clinical and physical exam findings are described. Management strategies for the treatment of drug eruptions are outlined. This is the first case report that we know of describing a diffuse drug eruption associated with sclerotherapy. It is important to recognize the possibility of diffuse drug eruptions secondary to sclerotherapy treatment so that expectant management may be initiated expeditiously in affected patients.

Case Report

A 64-year-old woman with hypertension and bilateral lower extremity telangiectasias presented from an outside facility following several sclerotherapy injections using polidocanol over a three-month period. Following the first session, she developed a diffuse eczematous rash over the bilateral lower extremities associated with pruritis and erythema (Figure 1). She had no history of dermatitis prior to this episode. As sclerotherapy sessions continued, the rash progressed to involve the torso, neck, and upper extremities, sparing her face and dorsum of her hands. She denied any recent travel, change in detergent, soaps, or perfumes.

The patient was referred for evaluation by a dermatologist, who initially diagnosed diffuse dermatitis based on clinical exam. She was prescribed a series of treatment modalities including antibiotics, antihistamines, and steroids without improvement. Subsequent biopsies of the rash (Figure 2) revealed hyperkeratosis with foci of parakeratosis, acanthosis, spongiosis, focal basilar vacuolar alteration, and scattered apoptotic keratinocytes throughout the specimen. There were many pseudo-pautrier microabcesses containing histiocytes and Langerhans cells, as well as foci of lymphocyte exocytosis, some associated with spongiosis and alignment with the basilar epidermis. The dermis contained a mild perivascular lymphohistiocytic infiltrate and scattered pigmented macrophages. Taken together, these findings were consistent with a lymphocytic drug reaction with mild lymphocytic atypia.
A thorough review of the patient’s history revealed that her anti-hypertensive regimen had recently changed from lisinopril to amlodipine just prior to her first sclerotherapy session. Although the etiology of the drug eruption was unclear, the patient was transitioned back to lisinopril and started on triamcinolone ointment and hydroxyzine for symptomatic relief. She experienced near-complete resolution of her drug-induced dermatitis within 2 weeks of these changes.

Several weeks later, the patient was restarted on amlodipine in an effort to optimize her blood pressure control. Her dermatitis did not worsen with the reintroduction of amlodipine. She has had no further sclerotherapy sessions, and remains dermatitis-free at this time. Based on these findings, it appears that injection of sclerosant may have been responsible for the patient’s drug eruption.

**Discussion**

Dermatologic reactions are rare, but recognized, side effects of many drugs [1-7]. These reactions can be toxic, metabolic, or allergic in nature. Certain patient populations are at increased risk for developing drug eruptions, including women, patients who are immune compromised, and those with auto-immune deficiencies. The most common drug reaction is an exanthematous rash, which accounts for 40% of all drug eruptions and is often associated with pruritis and fever [8]. More serious reactions, such as Stevens-Johnson syndrome, are also known to occur [1]. However, diffuse dermatologic reactions are not a previously recognized side effect of sclerosant injection.

Sclerotherapy is a widely accepted technique to treat both aesthetic and pathophysiologic disorders of the superficial venous system. It is particularly useful for small caliber veins, as the effectiveness of sclerosant is dependent upon the area of the internal lumen of the vein that comes in contact with the injected agent. Studies suggest there may be more than 70% improvement in telangiectasias after only two treatment sessions [9]. Sclerotherapy is considered the preferred method of treatment for telangiectasias because it has equivalent or better outcomes than laser therapy, but is better tolerated due to less discomfort [10,11]. There are several sclerosing agents available for use, including osmotic, alcohol, and detergent agents. Studies suggest that osmotic and detergent agents have equivalent efficacy in the treatment of telangiectasias, while alcohol agents may have somewhat better efficacy. Polidocanol, the commonly used detergent agent, is known to be associated with less pain than other sclerosing agents [12-14].

Dermatologic eruptions localized to sclerotherapy injection sites have been previously documented. For example, granuloma annulare following sclerotherapy has been described, presumably as the result of trauma to the skin from the injection itself combined with the introduction of foreign material (i.e., sclerosant) [15]. Urticaria at the injection site and telangiectatic matting anywhere on the lower extremity are common side effects related to the injection of sclerosant [16]. Hyperpigmentation can also occur, usually in a dose-dependent manner that is directly proportional to the concentration of the sclerosant used.

More severe reactions, such as Nicolau’s livedo dermatitis, infrequently occur following sclerotherapy, but are usually confined to the injection site [17,18]. Patients affected by this syndrome experience rapid onset of severe pain with erythema, blanching, and a reticular rash at the site of injection, followed skin and deep tissue necrosis that leads to disfiguring scars. The rash does not usually spread systemically, and is much more severe than the patient’s reaction that we describe. Systemic allergic reactions can occur with any of the sclerosing agents, but generally present with traditional allergy symptoms such as shortness of breath, edema, and multisystem organ dysfunction [16]. Diffuse drug-induced dermatitis distant from the local area of the injection site is not, to our knowledge, a previously recognized side effect of sclerotherapy.

The most important step in treating a drug eruption is identification and cessation of the offending agent. Additionally, topical corticosteroids and oral antihistamines can be used for symptomatic relief of pruritis or pain. NSAIDs may also be administered to those patients who develop a fever as a component of their reaction [19]. Ultimately, once the offending agent is withdrawn, supportive care is the first line of therapy. Most drug eruptions are self-limited, and will resolve over 2-6 weeks.

**Conclusion**

Sclerotherapy is recognized as a safe and effective treatment for lower extremity telangiectasias. Although dermatologic reactions local to the injection site are not uncommon, these are usually mild and self-limited. Rarely, patients may experience more diffuse dermatologic reactions following injection of sclerosant. If unexpected or atypical skin reactions occur, sclerotherapy should be discontinued until an...
underlying etiology has been determined. These patients should be managed expectantly, and treated for symptomatic control.

References